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Abstract
Expression of the a2b1 integrin, a receptor for collagens and laminin, is altered during tumor progression. Recent studies
have linked polymorphisms in the a2 integrin gene with oral, squamous cell carcinoma (SCC). To determine the a2b1
integrin’s role in SCC progression, we crossed a2-null mice with K14-HPV16 transgenic animals. Pathological progression to
invasive carcinoma was evaluated in HPV-positive, a2-null (HPV/KO) and HPV-positive, wild-type (HPV/WT) animals. a2b1
integrin expression stimulated progression from hyperplasia and papillomatosis to dysplasia with concomitant dermal mast
cell infiltration. Moreover, lymph node metastasis was decreased by 31.3% in HPV/KO, compared to HPV/WT, animals. To
evaluate the integrin-specific impact on the malignant epithelium versus the microenvironment, we developed primary
tumor cell lines. Although transition from dysplasia to carcinoma was unaltered during spontaneous tumor development,
isolated primary HPV/KO SCC cell lines demonstrated decreased migration and invasion, compared to HPV/WT cells. When
HPV/WT and HPV/KO SCC cells were orthotopically injected into WT or KO hosts, tumor a2b1 integrin expression resulted in
decreased tumor latency, regardless of host integrin status. HPV/WT SCC lines failed to demonstrate a proliferative
advantage in vitro, however, the HPV/WT tumors demonstrated increased growth compared to HPV/KO SCC lines in vivo.
Although contributions of the integrin to the microenvironment cannot be excluded, our studies indicate that a2b1 integrin
expression by HPV-transformed keratinocytes modulates SCC growth and progression.
Citation: Tran T, Barlow B, O’Rear L, Jarvis B, Li Z, et al. (2011) Loss of the a2b1 Integrin Alters Human Papilloma Virus-Induced Squamous Carcinoma Progression
In Vivo and In Vitro. PLoS ONE 6(10): e26858. doi:10.1371/journal.pone.0026858
Editor: Meenhard Herlyn, Wistar Institute Program, United States of America
Received May 11, 2011; Accepted October 5, 2011; Published October 27, 2011
Copyright:  2011 Tran et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by National Institutes of Health (NIH) grants RO1CA115984-01 and 2RO1CA098027-07A1 as well as by the Vanderbilt
Medical Scientist Training Program National Institute of General Medical Sciences/NIH T32 GM007347. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mary.zutter@vanderbilt.edu
Introduction
Cancers arise from the accumulation of genetic mutations that
alter cell proliferation, differentiation, and tissue organization.
Infection with Human Papilloma Virus (HPV) causes 100% of
cervical cancer, 90% of anal cancer, 40% of vulvar and vaginal
cancer, 15%–35% of oropharyngeal cancers, and approximately
3% of oral cancers [1,2,3]. Approximately 6.2 million new HPV
infections occur each year globally, with 20 million women
currently infected. Cervical cancer is the 7
th most common cause
of death in women worldwide. Arbeit, Coussens, and Hanahan
developed a transgenic mouse model of epithelial carcinogenesis in
which the HPV 16 early region genes were expressed in basal
keratinocytes under the control of the keratin 14 promoter
[4,5,6,7,8,9,10,11,12,13,14,15,16]. This model of squamous
epithelial carcinogenesis mimics viral-induced tumor progression
in humans.
Cancer progression and metastasis do not solely rely upon the
genetic and epigenetic events within the tumor cell, but also on
changes in the microenvironment [17,18,19]. Integrins mediate
both cell-extracellular matrix (ECM) and cell-cell adhesion
[20,21,22,23,24,25,26,27]. As mediators of cell adhesive behavior,
integrins play a critical role in tumor progression and metastasis
[21,28]. The a2b1 integrin, primarily a collagen and laminin
receptor, is highly expressed on basal keratinocytes where it is
involved in adhesion to basement membrane collagens and
migration on laminin 5. The integrin is also expressed on many
epithelial cells, activated endothelial cells, and some inflammatory
cells [4,5,6,29,30]. Previous studies suggest that a2b1integrin
expression is altered in vivo during progression of breast, lung, and
prostate cancers [31,32,33,34,35]. Recent studies have linked
polymorphisms in the a2b1 integrin with oral, squamous cell
carcinoma (SCC) [36]. Dyce et al. demonstrated that human SCC
cell lines that expressed high levels of the a2b1 integrin were more
invasive than cells with low integrin expression [37].
To determine the role of a2b1 integrin expression in squamous
epithelial carcinogenesis, we chose the K14-HPV16 model for
several reasons: 1. Expression of the a2b1 integrin on squamous
epithelial cells is regulated in a differentiation-dependent manner.
2. The K14-HPV16 model investigates the complex interplay
between the malignant cells and the host immune system,
including a requirement for mast cells in the progression towards
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a2b1 integrin expression on connective tissue mast cells and
showed that the integrin participated in mast cell activation in
response to specific pathogens. 4. HPV-stimulated carcinoma is
highly relevant to human disease and represents a significant
public health burden.
We now show that a2b1 integrin expression promotes early
preneoplastic dysplasia from hyperplasia and papillomatosis to
dysplasia. Decreased dysplasia in the HPV/KO mice was associated
with decreased recruitment of mast cells at early time points.
Although, loss of a2b1 integrin expression did not affect tumor
latency, prevalence, tumor growth, or histologic grade, metastasis to
the regional lymph nodes was decreased by 31.3%. Since these
studies were conducted in animals in which the a2b1i n t e g r i nw a s
globally deleted, primary tumor cell lines were developed. Isolated,
primary HPV/WT, but not HPV/KO SCC cell lines, migrated
rapidly and invaded through a matrix of type I collagen. Following
orthotopic injection of HPV/WT and HPV/KO cells into either
WT or KO mice, HPV/WT SCC cells formed tumors with a short
latency and rapid growth. In contrast, HPV/KO SCC cells either
failed toformtumors orgrew significantlyslowerthanthe HPV/WT
tumorcells.Integrin statusofthe hostanimaldidnot influencetumor
development. Therefore, our data from both the spontaneous in vivo
and orthotopic primary tumor cell transplantation in vivo models
support a role for a2b1 integrin expression by the HPV oncogene-
transformed SCCs in malignant progression. The differences
between the spontaneous model and the orthotopic injection model
suggest that many factors play a role in tumor progression in vivo.
Materials and Methods
Ethics Statement
Mice were housed in pathogen-free conditions at Vanderbilt
University Medical Center in strict compliance with national and
institutional animal welfare regulations; all animal experiments
were approved by Vanderbilt’s IACUC protocol M/10/002.
Animals and Tumor Measurement
The a2b1 integrin-deficient mice on the FVB/N background
were crossed with congenic K14-HPV16 transgenic mice, a
generous gift from Lisa Coussens, to generate K14-HPV16, a2-
null (HPV/KO) or wild-type (HPV/WT) mice [38]. Non-K14-
HPV16-transgenic littermates were used as controls. Mice were
monitored weekly for tumor development; tumor volume was
calculated as V=0.526A6B
2, where V is the volume, A is the
largest diameter, and B is the shortest diameter. Once tumors
reached a maximum diameter of at least 10 mm, affected animals
were sacrificed, and tumors, blood, ears, and superficial lymph
nodes were harvested.
Histology
Tumor and ear morphology was evaluated on formalin-fixed,
paraffin-embedded, and hematoxylin and eosin stained sections.
Tumors were classified according to the WHO system of
differentiation (1+ = well, 2+ = moderate, 3+ = poorly, and
4+ = anaplastic/spindle cell) [8]. Ear skin was analyzed for the
presence or absence of hyperplasia, papillomatosis, or dysplasia.
The number of toluidine blue-stained mast cells was quantitated
using the Metamorph imaging system (Molecular Devices,
Sunnyvale, CA) [39].
Immunohistochemistry and Immunofluorescence
Immunohistochemical identification of wide-spectrum cytoker-
atin expressing metastatic tumor cells was performed on lymph
node sections using anti-bovine WSCK antibody, EnVision+
polyclonal labeled polymer, and DAB substrate (all from Dako,
Carpinteria, CA). Immunofluorescence analysis of primary tumor
cells was conducted on cells plated on coverslips with anti-LYVE-1
(Abcam, Cambridge, MA), anti-WSCK (Dako), and DAPI
(Invitrogen). Secondary antibodies included Alexa Fluors 568
and 488 (Invitrogen). Imaging was performed using a Nikon
Eclipse 80i microscope and quantitated using ImageJ (NIH,
Bethesda, MD).
Flow Cytometry
Flow cytometric analyses of peripheral blood and infiltrates into
ear skin and tumors were performed on a 3-laser, BD LSR II Flow
Cytometer in the Vanderbilt Medical Center Flow Cytometry
Shared Resource, and data analysis was performed using FlowJo
(Tree Star, Inc., Ashland, OR). Tumor-bearing animals were
sacrificed and tumor, ear, and peripheral blood leukocytes were
collected and processed, as described previously [15]. Cell
suspensions were evaluated with either pre-conjugated BD
Pharmingen antibodies against mouse Gr-1 or NK1.1, eBioscience
antibodies (San Diego, CA) against mouse c-kit, CD11b, F4/80,
CD3e, B220, CD4, CD25, or Foxp3, or appropriate isotype
controls. Expression of the a2 integrin subunit on primary SCC
cells was determined by flow cytometric analysis using anti-CD49b
(BD Pharmingen) or IgG control (BD Pharmingen).
Cell Culture
Isolation of Primary Tumor Cells. Primary tumors were
dissected under sterile conditions, finely minced, and cultured in
primary tumor media containing DMEM-F12 (Mediatech, Inc.,
Manassas, VA) supplemented with 5% FBS (Atlanta Biologicals,
Lawrenceville, GA), 0.01 mg/mL human EGF (Pepro Tech,
Rocky Hill, NJ), 1 mg/mL hydrocortisone (Sigma-Aldrich, St.
Louis, MO), 0.1 mg/mL cholera toxin (Calbiochem, La Jolla, CA),
0.3 units of insulin (Novo Nordisk, Princeton, NJ), and 100 units of
penicillin/streptomycin (Mediatech, Inc.) at 37uCi n5 %C O 2.
Proliferation Assay. HPV/WT or HPV/KO tumor cells
(2610
3) were plated on either collagen type I (BD Biosciences
Discovery Labware, Bedford, MA) (100 mg/mL), fibronectin (BD
Biosciences Discovery Labware) (100 mg/mL), or plastic and
incubated in primary tumor media. Cell proliferation was evaluated
every 24 hours using the CellTiter 96 AQueous Non-Radioactive
Cell Proliferation Assay (Promega Corporation, Madison, WI),
according to the manufacturer’s protocol. Plates were read at
490 nm on a Molecular Devices Emax Precision Microplate Reader,
and data was analyzed using Softmax (Molecular Devices).
Transfection with the a2 Integrin Subunit. The mouse
full-length a2( m a2) integrin subunit (NCBI GenBank Z29987), a
gift from Jeffrey Bergelson, was inserted into the mammalian pSRa
expression vector. Clones were selected and verified by sequencing.
HPV/KO-2 cells were transfected with 20 mg of either pSRa-ma2
or empty pSRa vector using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) according to manufacturer’s protocol.
Adhesion Assay. The ability of primary tumor cells
(1.7610
4 cells/well) to adhere at 37uC for 1 hour to either
collagen type I (20 mg/mL) or fibronectin (20 mg/mL) was
determined using established protocols in the presence of 2 mM
MgCl2 (Sigma-Aldrich) or 2 mM EDTA (Sigma-Aldrich) [40].
The optical density of the plate was read at 405 nm on a
Molecular Devices Emax Precision Microplate Reader, and data
was analyzed using Softmax (Molecular Devices).
Migration and Invasion Assay. Cell migration and invasion
assays were performed using a modification of the protocol
described previously [41]. HPV/WT or HPV/KO primary tumor
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4) in primary tumor media containing 1.5% FBS were
placed on the upper membrane of 0.8 mm pore transwell filters
(Corning Incorporated Life Sciences, Lowell, MA), which was
either uncoated or coated with collagen type I (100 mg/mL).
Primary tumor media containing 5% FBS was placed in the lower
chamber. The number of cells migrating to the lower chamber at
37uC after 18 hours was determined by counting the number of
cells in 3 random high power (10X magnification) fields.
Orthotopic Injection of Primary Tumor Cells
Tumor cells (1610
6) derived from two separate HPV/WT or
HPV/KO lines were injected subcutaneously into the interscap-
ular region of either WT or KO, 4-5-week-old FVB/N hosts.
Tumors were measured twice a week; volumes were calculated as
previously described.
Statistical Analyses
Statistics were performed using student’s t-tests, unless otherwise
noted. Contingency table analyses with tests for trend were used to
analyze all distributions of tumor grades and tumor multiplicity.
Tumor volume growth curves were analyzed by spaghetti plots
with curve regression analysis to determine average slopes. Chi-
squared tests were performed to determine significance of
preneoplastic ear histology. Mann-Whitney U tests were per-
formed for analyses of mast cell ear histology, and for analyzing
specific groups within inflammatory populations in all flow
cytometry data. P-values of #0.05 were considered significant.
Analyses were performed using Stata (StataCorp LP, College
Station, TX) and GraphPad Prism (La Jolla, CA).
Results
The a2b1 Integrin Promotes HPV-induced Squamous
Epithelial Dysplasia
HPV-induced squamous carcinogenesis involves the step-wise
progression from hyperplasia to papillomatosis, to dysplasia, to
carcinoma in situ (CIS) and finally to invasive and metastatic cancer
[10,12,14,42,43,44,45]. To define the role of the a2b1 integrin in a
multi-step, inflammation-driven epithelial carcinogenesis model, we
crossed the a2b1 integrin-deficient mouse on an FVB/n background
with congenic K14-HPV16 mice to generate K14-HPV16/wild-
type (HPV/WT) and K14-HPV16/a2-null (HPV/KO) mice.
Preneoplastic progression, including hyperplasia, papillomatosis,
or dysplasia, was defined in the ear skin of HPV/WT and HPV/
KOmiceat 3-,6-,or9-months-of-age,or atthetime ofsacrificedue
to the development of invasive, squamous carcinoma at another
location. By 6-months-of-age, there were significant differences in
dysplasia and papillomatosis between the two genotypes: approx-
imately 15% of HPV/WT animals (n=20), but none of the HPV/
KOanimals(n=25), developeddysplasia.In contrast,theincidence
of papillomatosis was almost double in the HPV/KO animals
(p=0.0384). Differences in papillomatosis and dysplasia between
HPV/KO and HPV/WT ears were also present at later time points
(9-months p=0.0637; time of sacrifice p=0.00169) (Figure 1A).
Figure 1. Loss of the a2b1 integrin enhanced HPV-induced papillomatosis but limited dysplasia and preneoplastic mast cell
infiltration. A, The percentage of HPV/WT and HPV/KO animals with hyperplasia, papillomatosis, or dysplasia at 3-, 6-, and 9-months-of-age, and at
sacrifice was determined by morphological examination of ear tissue. The incidence of papillomatosis was significantly increased, while dysplasia was
significantly decreased in HPV/KO animals, compared to age-matched, HPV/WT littermates, at 6-months-of-age and at sacrifice (3-months p=0.304,
HPV/WT n=28, HPV/KO n=27; 6-months p=0.0384, HPV/WT n=20, HPV/KO n=25; 9-months p=0.0637, HPV/WT n=17, HPV/KO n=13; time-of-
sacrifice p=0.00169, HPV/WT n=95, HPV/KO n=68). B, Mast cell infiltration into the ear dermis of HPV/WT and HPV/KO animals was quantitated at 3-,
6-, and 9-months-of-age, and at sacrifice. Ear skin of HPV/WT and HPV/KO animals at 3-months-of-age have similar numbers of mast cells (p=0.58,
n=10 for both groups). At 6-months, HPV/KO ears had decreased numbers of mast cells compared to age-matched HPV/WT littermates (p=0.019,
n=10 for both groups). Over time, dermal mast cell infiltration decreased. The number of mast cells in the ear skin of HPV/WT and HPV/KO animals
was similar at 9 months and at sacrifice (9 months p=0.32 , n=5 for both groups; time of sacrifice p=0.23, n=5 for both groups). Bars represent
mean 6 SEM of 3 random images per tissue sample. C, A representative toluidine blue-stained section of HPV/WT and HPV/KO premalignant ear
tissue at 6 months. Arrows indicate toluidine blue positive cells. Scale bar =200 mm.
doi:10.1371/journal.pone.0026858.g001
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neoplastic progression in K14-HPV16 transgenic animals [16].
Therefore, the recruitment of inflammatory cells to the skin of
HPV/WT and HPV/KO animals at early time points was
investigated. There was no significant difference in the total
number of CD45-positive cells recruited to the dermis of HPV/
WT and HPV/KO mice at either 3- or 6-months-of-age (p=0.29
and 0.90, respectively; data not shown). At 3-months-of-age, there
was also no difference in the number of dermal mast cells in HPV/
WT and HPV/KO mouse ears (p=0.58). In contrast, by 6-
months-of-age, there were significantly fewer resident mast cells in
HPV/KO than in HPV/WT ears (p=0.019). Mast cell numbers
decreased in ear tissue over time but were similar at 9-months-of-
age and at the time of sacrifice between HPV/WT and HPV/KO
ears (n=0.32 and 0.23, respectively) (Figure 1B and 1C). While
the quantity of acute mast cells was altered in the preneoplastic
ears of K14-HPV16 transgenic mice, detailed studies examining
inflammatory populations at the time of animal sacrifice revealed
that chronic inflammation is not substantially altered in blood,
non-tumorigenic ear, or tumor tissue with integrin loss. In this
inflammation-driven tumor model, immune cell differences were
dependent on presence of the K14-HPV16 transgene, but
ultimately, the a2b1 integrin contributes minimally to long-term,
chronic inflammation (Figure S1 and Table S1).
The a2b1 Integrin Regulates Development of Sebaceous
Adenocarcinoma But Not Invasive Squamous Cell
Carcinoma
To determine the impact of a2b1 integrin expression on
progression from dysplasia to invasive carcinoma, tumor latency
and prevalence in HPV/KO and HPV/WT animals were
determined. Tumor latency was similar in HPV/KO and HPV/
WT animals (p=0.11) (Figure 2A). No differences exist in SCC
development between HPV/WT (49.4%) and HPV/KO (58.9%)
mice by 10-months-of-age (n=170 and 107, respectively;
p=0.12). The tumor growth rate, number of tumors per animal,
and anatomic location of the SCCs were indistinguishable in
HPV/KO animals, as compared to HPV/WT mice (Figure S2A,
S2B, and data not shown). Therefore, although a2b1 integrin
expression promotes epithelial dysplasia, expression does not
stimulate tumor progression from dysplasia to invasive carcinoma
in the HPV-stimulated model of squamous cancer.
Previous studies demonstrated that a2b1 integrin expression
may be associated with normal, regulated, epithelial differentiation
and that altered expression of the integrin may be seen in different
subtypes of cancer. To determine whether a2b1 integrin
expression or lack thereof affected tumor cell differentiation,
invasive HPV/WT and HPV/KO tumors were analyzed
histologically. SCC differentiation was graded based on the
Broder’s four-tier system [8]. There was no difference in tumor
grade between HPV/WT and HPV/KO animals (p=0.57),
suggesting that the a2b1 integrin did not ultimately impact
squamous differentiation in the K14-HPV16 background (Figure
S2C). Even though the majority of tumors arising in the wild-type
K14-HPV16 background were SCCs, occasionally, these animals
developed sebaceous adenocarcinomas, either alone or in areas
with concomitant SCC growth [46]. In HPV/KO mice,
compared to HPV/WT mice, pure sebaceous adenocarcinomas
represented 13.75% versus 4.00% of the tumors, respectively
(p=0.028) (Figure 2B).
Loss of the a2b1 Integrin by HPV-Induced SCC Decreases
Lymph Node Metastasis
Previous studies have shown that approximately 30% of SCCs
in the K14-HPV16 mouse metastasize to regional lymph nodes
[46]. Consistent with the literature, in our study, 34.8% of HPV/
WT tumors metastasized. In contrast, only 23.9% of HPV/KO
SCCs metastasized to the lymph nodes (Figure 3A). The presence
of lymph node metastasis was verified by immunohistochemical
staining for cytokeratin (Figure 3B). Therefore, although there was
no difference in tumor growth or tumor latency, expression of the
a2b1 integrin promoted tumor metastasis to regional lymph
nodes. The difference in metastasis between HPV/WT and HPV/
KO animals was not statistically significant (p=0.14) due to
limitations of study size. However, the incidence of lymph node
metastasis in HPV/KO mice was decreased by 31.3%, compared
to metastasis in the HPV/WT animals. The odds ratio for
developing lymph node metastasis in the HPV/WT animals
relative to HPV/KO mice was 1.7 (HVP/KO mice 95%
confidence interval is 18.3–54.3%; HPV/WT 95% confidence
interval is 34.7–81.9%).
Figure 2. Expression of the a2b1 integrin modulates the
incidence of sebaceous adenocarcinoma formation, but not
SCC. A, Kaplan-Meier plots of tumor-free HPV/WT and HPV/KO mice.
Tumor development was recorded when a visible tumor nodule
formed. Latency (time to tumor development) was similar in HPV/WT
(n=146) and HPV/KO (n=94) mice (p=0.11). B, The percentage of HPV/
WT and HPV/KO animals that developed either SCC or sebaceous
adenocarcinoma was determined morphologically. Development of
sebaceous adenocarcinoma was significantly increased in HPV/KO
animals (n=80) compared to HPV/WT mice (n=100) (p=0.028).
doi:10.1371/journal.pone.0026858.g002
Figure 3. a2b1 integrin expression promoted lymph node
metastasis. A, The percentage of HPV/WT and HPV/KO animals with
SCC that developed regional lymph node metastasis was determined
by morphologic and immunohistochemical analysis of superficial lymph
nodes. The HPV/KO animals with tumors (n=71) developed metastasis
in 23.9% of cases; HPV/WT animals with tumors (n=92) developed
metastasis in 34.8% of cases (p=0.14; odds ratio 1.7). B, Representative
section of a regional lymph node from an HPV/WT animal evaluated by
immunohistochemistry for detection of WSCK. The metastatic tumor
cells express WSCK (Met) and are surrounded by normal lymph node
parenchyma (LN). Scale bar=200 mm.
doi:10.1371/journal.pone.0026858.g003
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Migration and Invasion
To begindissectingintegrin-dependentchanges inthetumorcells
versus by cells of the host microenvironment, we focused on the
contribution of a2b1 integrin expression by the malignant epithelial
cells in tumor progression. Primary tumor cells from HPV/WT and
HPV/KO tumors were harvested and two HPV/WT (HPV/WT-1
and HPV/WT-2) and two HPV/KO (HPV/KO-1 and HPV/KO-
2) squamous carcinoma cell lines were developed. The epithelial
origin of the tumor cells was confirmed by cytokeratin staining
(Figure 4A). The HPV/WT, but not the HPV/KO primary tumor
cell lines expressed the a2b1 integrin, as determined by flow
cytometric analysis (Figure 4B). Both HPV/WT cells, but not the
HPV/KO cells, adhered to type I collagen in a Mg
2+ dependent
and EDTA
2+-inhibitable manner, as did a positive control,
NMuMG-X2C2 (derived from the NMuMG3 line stably transfect-
ed with full length human a2 integrin subunit) (Figure 4C) [40]. All
cells adhered to fibronectin (data not shown). Both HPV/WT and
HPV/KO cells proliferated at a similar rate on collagen,
fibronectin, or plastic (p=0.35, p=0.33, and p=0.42, respectively)
(Figure S3). Therefore, integrin expression did not alter tumor cell
proliferation of HPV-driven squamous tumor cells. Although
presence of the a2b1 integrin did not alter cell proliferation,
expression of the integrin stimulated cell migration and cell invasion
in vitro. HPV/WT, but not HPV/KO, cells robustly migrated in vitro
in a three-dimensional transwell migration assay (p,0.0001) and
invaded throughabarrieroftypeIcollagen(p,0.0001)(Figure 4D).
To determine if a2b1 integrin expression alone could mediate the
migratory ability of HPV/KO cell lines, expression of the a2b1
integrinintheHPV/KO-2cellline was rescued by transfection with a
murine a2-integrin subunit expression vector (HPV/KO-2-ma2
+)o r
control vector (HPV/KO-2-VC). Asd e t e r m i n e db yf l o wc y t o m e t r i c
analysis, HPV/KO-2-ma2
+ cells expressed high levels of the murine
a2b1 integrin (Figure 4E). Re-expression of the a2 integrin subunit
restored the ability of the HPV/KO-2-ma2
+ c e l l st oa d h e r et ot y p eI
collagen in a Mg
2+ dependent and EDTA
2+-inhibitable manner,
when compared to HPV/KO-2-VC cells (p=0.015) (Figure 4F).
Restoration of murine a2-integrin expression by HPV/KO-2 SCCs
also rescued the migratory and invasive ability of the tumor cells
through type I collagen, when compared to the control transfectants
(p=0.0002 and p,0.0001, respectively) (Figure 4G).
a2b1 Integrin Expression by Squamous Epithelium
Promotes Tumor Growth In Vivo
To determine the impact of a2b1 integrin expression by the
tumor cells on tumor growth and latency, the primary tumor cell
lines derived from HPV/WT and HPV/KO animals (HPV/WT-
1 and -2 and HPV/KO-1 and -2) were orthotopically injected into
nontransgenic, wild-type or a2-null mice. The HPV/WT tumor
cells grew rapidly when placed in either wild-type or a2-null mice.
In contrast, the HPV/KO tumor cells demonstrated increased
latency (p=0.0003) and markedly decreased tumor growth rates
(p=0.034) when compared to mice injected with HPV/WT SCC
cells, regardless of recipient mouse integrin status (Figure 5A and
5B). The short time span of orthotopic tumor growth was not
permissive for the development of spontaneous metastasis. These
results demonstrate that the a2b1 integrin expression promotes
tumor growth and progression of SCC in a manner independent
of the host microenvironment.
Discussion
Using the K14-HPV16 cancer model, we demonstrate that lack
of a2b1 integrin expression results in decreased progression from
epithelial papillomatosis to dysplasia, increased formation of
sebaceous adenocarcinomas instead of SCCs, and modestly
decreased lymph node metastasis. Although global loss of the
a2b1 integrin in all HPV/KO mouse cells did not affect tumor
latency, growth, or multiplicity in vivo, primary tumor cells derived
from HPV/KO animals demonstrated diminished cell migration
and invasion in vitro and decreased tumor formation and growth
when implanted orthotopically into non-K14-HPV16 transgenic
wild-type or a2-null animals. Additionally, the host’s integrin
status did not impact tumor formation or growth, thereby
suggesting that a2b1 integrin expression by the tumor microen-
vironment is not responsible for tumor progression in this model.
Diminished epithelial dysplasia and enhanced papillomatosis in
HPV/KO mice suggest that the a2b1 integrin plays a role in
regulatingepithelial differentiationandpromoting the initialstepsof
neoplasia. The mast cell reduction in 6-month-old HPV/KO mice
may promote papillomatosis. On one hand, the reduction in mast
cells may limit the further progression of papillomas to carcinoma.
On the other hand,mast cell deficient animals have been shown to
be more susceptible to papilloma formation than their wild-type
counterparts in other models [47]. Therefore, while these
inflammatory cells help drive the hyperplasia and dysplasia
associated with squamous carcinogenesis, they may be affecting
rates of papillomatosis differently [10]. At the stage of invasive
carcinoma, neither tumor latency, growth, or differentiation, i.e.
grade, was different in HPV/WT and HPV/KO mice. In
concordance with in vivo murine studies, demonstrating that
dysregulated expression of the a2b1 integrin did not alter malignant
conversion in SCC, a2b1 integrin expression in the K14-HPV16
model did not affect later aspects of tumor progression [48].
Although no difference in SCC progression was noted in vivo,
when primary squamous carcinoma cells isolated from HPV/WT
or HPV/KO mice were reintroduced orthotopically into either
non-K14-HPV16 transgenic, wild-type or a2-null animals, the
HPV/WT tumor cells, but not the HPV/KO tumor cells
engrafted and grew rapidly. The HPV/WT tumor cells were
significantly more migratory and invasive in vitro. Integrin loss on
SCC cells resulted in reduced migration but even more striking
deficiencies in invasion through collagen type I. [49,50]. Our data
suggest that a2b1 integrin-mediated interaction of squamous
carcinoma cells with type I collagen, which is abundant in the
dermis of mice and humans, may function to promote cancer cell
migration and invasion, as seen in other models [49][[50]. HPV/
KO tumor cells transfected with the wild-type mouse a2-integrin
subunit failed to maintain integrin expression in vivo, thus
preventing the analysis of integrin rescue in a SCC model of in
vivo tumor formation and growth.
In patients with SCC, the development of lymph node
metastasis is a predictor of poor outcome [51,52]. Loss of the
a2b1 integrin in the K14-HPV16 model resulted in decreased
lymph node metastasis to regional lymph nodes by 31.3%. This
correlates with an odds ratio of 1.7 for developing lymph node
metastasis in the HPV/WT animals relative to HPV/KO mice.
These data were quite surprising in light of our own recently
published data that the a2b1 integrin acts as a tumor metastasis
suppressor in breast and prostate cancer. In the mouse mammary
tumor virus-Neu (MMTV-Neu) transgenic mouse model of breast
cancer, lack of a2b1 integrin expression resulted in modestly
decreased mammary tumor latency and markedly increased
cancer metastasis [53].
The discordant contributions of the a2b1 integrin to metastasis
in the HPV-stimulated model of SCC versus the neu-driven model
of breast cancer raise interesting questions. First, the two models
deal with distinctly different subtypes of carcinoma, SCC and
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PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e26858Figure 4. Expression of the a2b1 integrin stimulates SCC migration and invasion in vitro. A, Primary HPV/WT and HPV/KO tumor cell lines
were stained with anti-WSCK to demonstrate the epithelial origin of the cells. B, Flow cytometric analysis using an a2 subunit antibody verified
integrin expression on wild-type SCC lines, HPV/WT-1 and -2, and absence of integrin expression on a2-null lines HPV/KO-1 and -2. C, HPV/WT-1 and
-2 SCC lines adhered to type I collagen in a Mg
2+-dependent and EDTA-inhibited manner. The X2C2 control cells that express human full-length a2
cDNA served as a positive control. The HPV/KO-1 and -2 cells failed to adhere to type I collagen (p,0.0001). Bars represent mean 6 SEM of 2
experiments, performed in duplicate. D, HPV/WT-1 and -2 cells exhibited significantly enhanced migration and invasion compared to HPV/KO-1 and
-2 cells, cells (p,0.0001 and p,0.0001, respectively). Bars represent mean 6 SEM of 3 random photos of transwell experiments, performed in
duplicate. E, Transfection of the HPV/KO-2 line with pSRa vector containing the wild-type mouse aa2 integrin subunit (HPV/KO-2-maa2) restored
integrin levels to that found in wild-type SCC cells, as determined by flow cytometric analysis. F, Expression of the transfected maa2 subunit in HPV/
KO-2-maa2 cells rescued their ability to adhere to collagen, compared to empty vector control transfectants (HPV/KO-2-VC) (p=0.015). Bars represent
mean 6 SEM of 2 experiments, performed in duplicate. G, The ability of the HPV/KO-2-ma2 transfectants to migrate and invade was restored,
compared to HPV/KO-2-VC cells (p=0.0002 and p,0.0001, respectively). Bars represent mean 6 SEM of 3 random photos of transwell experiments,
performed in duplicate.
doi:10.1371/journal.pone.0026858.g004
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Perhaps the a2b1 integrin’s role in regulating the multistep process
of tumorigenesis is different depending on the cell of origin.
Second, the metastatic route and mechanisms of dissemination are
different between the two disease models. In the K14-HPV16
model, SCCs primarily metastasize via the lymphatics to regional
lymph nodes. In the MMTV-neu model, cancer metastasizes
primarily via the hematogenous route to the lungs. Third, the two
tumor models are driven by different oncogenes that function
distinctly. K14-HPV16 oncogenesis is triggered by expression of
early region HPV16 oncogenes, E6 and E7, which inactivate two
important tumor suppressor genes p53 and retinoblastoma,
respectively. In contrast, the MMTV-Neu model of mammary
cancer is driven by overexpression of the Neu tyrosine kinase that
stimulates activation of the ras/map kinase cascade. Fourth,
progression to carcinoma in the K14-HPV16 model requires the
protumorigenic activity of inflammatory cells. Neither tumorigen-
esis nor metastasis in the MMTV-Neu model is dependent on
recruitment of inflammatory cells. Fifth, the interaction of cancer
cells with the specific collagen content of their microenvironment
may be different. SCCs expressing the a2b1 integrin may have
increased migration and invasion along collagen type I fibers in
the skin, whereas receptor ligation with collagen type I may not be
as important in breast cancer cell motility.
In summary, the a2b1 integrin plays a complex role in tumor
progression through its contributions to both the malignant
epithelial cell and within the tumor microenvironment. Our data
are the first to suggest that integrin dependent regulation of tumor
progression may be specific to the tissue type and to the
mechanism of oncogenesis. In c-neu/HER2-positive breast
cancer, the a2b1 integrin is a metastasis suppressor. In contrast,
the a2b1 integrin promotes tumor metastasis in HPV-induced
squamous cancer, likely by increasing the migratory and invasive
ability of cells along collagen type I.
Supporting Information
Figure S1 The K14-HPV16 transgene, not the a2b1
integrin, mediates a robust inflammatory response. A–
C, Flow cytometric analysis of inflammatory cells was performed
on the blood and preneoplastic ears of non-K14HPV16 transgenic
wild-type (WT Ctrl) or a2-null (KO Ctrl) mice and HPV/WT and
HPV/KO animals, either with (SCC
+) or without tumors (SCC
2).
Similar analysis was also performed on the tumor tissue of HPV/
WT and HPV/KO mice. The percentage of inflammatory cell
subsets in HPV/WT and HPV/KO animals was compared to
non-transgenic controls. Inflammation was highly dependent upon
the presence of the K14-HPV16 transgene. Loss of the a2b1
integrin in HPV/KO ears increased the percentage of NK1.1
+
cells relative to HPV/WT ears in non-tumor bearing animals
(p=0.014). Additionally, there was a significant increase in CD3e
+
T cells in HPV/KO tumor infiltrates, when compared to HPV/
WT SCCs (p=0.033). (Number of samples analyzed in blood and
ear tissue: WT Ctrl n=9; KO Ctrl n=9; HPV/WT, SCC
+
n=12; HPV/WT, SCC
2 n=5; HPV/KO, SCC
+ n=14, HPV/
KO, SCC
2 n=4. Number of samples analyzed in tumor tissue:
HPV/WT, SCC
+ n=10 and HPV/KO, SCC
+ n=12.)
(TIF)
Figure S2 Loss of the a2b1 integrin does not alter SCC
growth, multiplicity, or grade. A, Tumor volumes were
measured weekly. The rate of tumor growth over time was
calculated from tumor volume regression slopes and plotted as a
function of time. No significant differences existed in the rates of
SCC growth between HPV/WT (n=22) and HPV/KO (n=22)
mice (p=0.37). B, Total tumor burden for each HPV/WT
(n=97) and HPV/KO mouse (n=73) was quantitated at the time
of sacrifice. No significant differences were found for the
multiplicity of tumor development (p=0.45). C, Since multiple
tumors may form on an animal, the highest grade scored was
Figure 5. Tumor-specific expression of the a2b1 integrin caused rapid tumor formation and increased tumor growth in vivo,
independent of host microenvironment. A, Orthotopic injections of SCC lines HPV/KO-1 and -2 into either non-K14-HPV16 transgenic, WT or a2-
null (KO) hosts resulted in increased tumor latency by approximately 5–10 days, as compared to SCC lines HPV/WT-1 and -2 (p=0.0003). Host integrin
status had no impact on tumor formation. Tumor latency was dependent on presence of the a2b1 integrin by the tumor cells (n=4 WT or 4 KO hosts
each for HPV/WT-1, HPV/WT-2, and HPV/KO-1 injections; n=4 WT and 5 KO hosts for HPV/KO-2 SCC cell injections). B, Orthotopically injected HPV/KO
tumor cells demonstrated decreased growth rate regardless of host integrin status, compared to HPV/WT SCC lines (p=0.034). Bars represent mean
6 SEM.
doi:10.1371/journal.pone.0026858.g005
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PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e26858considered for analysis of differentiation loss. No significant
differences were observed when considering the highest grade of
SCC that developed in HPV/WT (n=97) or HPV/KO (n=73)
mice (p=0.57).
(TIF)
Figure S3 In vitro proliferation of primary SCC cells
was unaffected by loss of the a2b1 integrin. Proliferation of
the HPV/WT-1 and -2 and HPV/KO-1 and -2 SCC lines when
adherent to collagen, fibronectin, or tissue culture plastic was
determined in vitro. Proliferation in vitro of HPV/WT and HPV/
KO lines was similar irrespective of the matrix (p=0.35, p=0.33,
p=0.42, respectively).
(TIF)
Table S1 Detailed Analysis of Inflammatory Cell Pop-
ulations in Blood, Preneoplastic Ears, and Tumors. WT
Ctrl and KO Ctrl animals were used to verify and establish
baseline inflammatory populations independent of the K14-
HPV16 transgene. Chi
2 probability with ties analysis was
performed on all 6 groups for each specific tissue; those found to
be significant or close to p,0.05 were analyzed further through
inter-comparison of the 6 groups by Mann-Whitney tests. The
groups in which significance was found are denoted as Genotype 1
vs. Genotype 2. Differences in inflammatory cells were found
between non-K14-HPV16 transgenic, control animals and those
expressing the K14-HPV16 transgene. Integrin-dependent differ-
ences were identified in the NK1.1-positive and CD3e-positive cell
populations. Non-neoplastic ear tissue in HPV/KO, SCC
2 mice
had increased NK1.1-positive cells than HPV/WT, SCC
2 ears
(p=0.014). HPV/KO SCCs contained more CD3e-positive cells
than HPV/WT tumors (p=0.033). T regulatory cells were defined
as CD4, CD25, and Foxp3 triple-positive cells as a percentage of
CD4-positive cells. (Blood and ear samples analyzed: WT Ctrl
n=9; KO Ctrl n=9; HPV/WT, SCC
+ n=12, HPV/WT, SCC
2
n=5; HPV/KO, SCC
+ n=14, HPV/KO, SCC
2 n=4. Tumor
tissue analyzed: HPV/WT, SCC
+ n=10 and HPV/KO, SCC
+
n=12). * represents p,0.05 ** represents p,0.001 *** represents
p,0.0001.
(DOCX)
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